RESUMO
No abstract available.
Assuntos
Acupuntura , Corpos Estranhos , Granuloma de Corpo Estranho , Hanseníase , Hanseníase VirchowianaRESUMO
Fibroelastolytic papulosis is an acquired elastic tissue disorder that includes the clinicopathological features of white fibrous papulosis of the neck (WFPN) and pseudoxanthoma elasticum-like papillary dermal elastosis (PXE-PDE). It is clinically characterized by discrete white papules occurring on the neck in middle-aged women and is histopathologically characterized by elastolysis and/or fibrosis in the upper dermis. An 80-year-old woman presented with multiple white papules on her anterior chest, which occurred 6 months prior to the presentation. Histopathological examination of a biopsy specimen revealed some degree of fibrosis and elastolysis in the upper dermis. Thus, the final diagnosis in this case was compatible with fibroelastolytic papulosis considering that this patient showed clinicopathological features of both WFPN and PXE-PDE. Notably, this is the first case report that describes fibroelastolytic papulosis confined exclusively to the anterior chest.
Assuntos
Idoso de 80 Anos ou mais , Feminino , Humanos , Biópsia , Derme , Diagnóstico , Tecido Elástico , Fibrose , Pescoço , TóraxRESUMO
Dermatofibroma is a fibrohistiocytic tumor of the skin that commonly occurs as a solitary lesion on the lower extremities of young women. Multiple eruptive dermatofibromas (MEDFs), defined as the presence of 5 to 8 dermatofibromas appearing within a period of 4 months, are rare, and the etiology of MEDFs remains unknown. However, MEDFs are frequently thought to be associated with altered immunity, such as autoimmune diseases and immunosuppression. It is unclear why MEDFs occur in association with these conditions, but this relationship may suggest that MEDFs are the result of an abortive immunoreactive process. We herein describe a middle-aged woman who developed multiple dermatofibroma. She had myasthenia gravis for 8 years, and developed MEDFs after undergoing oral corticosteroid treatment (245 mg/week) for 3 months. Therefore, our case suggests that the use of immunosuppressants is a more dominant factor for the development of MEDFs than underlying autoimmune diseases.